New4med Completes Its First Basivertebral Nerve Ablation Cases

New4med GmbH has officially launched its Basivertebral Nerve Ablation (BVNA) treatment in Europe.

“By offering BVNA to physicians, we are providing access to this treatment for people with vertebrogenic pain in Europe for the first time,” New4med CEO Daniel Seifert said. “Our goal is to make this high-growth therapeutic option available to a broad population of people with chronic low back pain.”

BVNA is a therapeutic treatment for vertebrogenic pain, a type of chronic low back pain associated with bony lesions on the vertebral endplates. The system—approved in Europe—is a minimally invasive, implant-free procedure that can be performed on both an inpatient and outpatient basis. It uses targeted radiofrequency energy to block the Nervus basivertebralis from transmitting pain signals to the brain, aiming to improve function and provide sustainable relief.

“Basivertebral Nerve Ablation has tremendous potential to help even more people living with chronic pain,” said Prof. Robert Pflugmacher, Mechernich.

“Access to this form of therapy now significantly enhances our treatment spectrum in the field of interventional chronic pain management,” added Prof. Andreas Kurth, a pioneer in the treatment of spinal metastasis with radiofrequency technology.

“We will continue to invest in developing our infrastructure to ensure the broadest possible market access and to meet the growing demand for this treatment.” explained Eric Schaber, New4med shareholder and strategy consultant. “This launch is the beginning of a series of new unique extremely innovative approaches that have the chance to revolutionize the current treatment options in spinal surgery.”

New4med GmbH is a German medtech startup developingt and distributing spinal surgery products designed to treat chronic back pain. New4med’s team consists of professionals from the medtech industry who bring their expertise and passion for innovation to the product development and distribution processes.